Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Mallinckrodt
McKinsey
Dow
Harvard Business School

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

FRAGMIN Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Fragmin patents expire, and what generic alternatives are available?

Fragmin is a drug marketed by Pfizer Inc and is included in one NDA.

The generic ingredient in FRAGMIN is dalteparin sodium. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the dalteparin sodium profile page.

Drug patent expirations by year for FRAGMIN
Drug Prices for FRAGMIN

See drug prices for FRAGMIN

Generic Entry Opportunity Date for FRAGMIN
Generic Entry Date for FRAGMIN*:
Constraining patent/regulatory exclusivity:
NEW PATIENT POPULATION
NDA:
Dosage:
INJECTABLE;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for FRAGMIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Sunnybrook Research InstitutePhase 3
Sunnybrook Health Sciences CentrePhase 3
Asan Medical CenterPhase 2

See all FRAGMIN clinical trials

Pharmacology for FRAGMIN

US Patents and Regulatory Information for FRAGMIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc FRAGMIN dalteparin sodium INJECTABLE;INJECTION 020287-008 Apr 4, 2002 DISCN No No   Start Trial   Start Trial   Start Trial
Pfizer Inc FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-009 May 1, 2007 RX Yes No   Start Trial   Start Trial   Start Trial
Pfizer Inc FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-005 Apr 4, 2002 RX Yes No   Start Trial   Start Trial   Start Trial
Pfizer Inc FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-010 May 1, 2007 RX Yes No   Start Trial   Start Trial   Start Trial
Pfizer Inc FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-001 Dec 22, 1994 RX Yes No   Start Trial   Start Trial   Start Trial
Pfizer Inc FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-003 Mar 18, 1996 RX Yes No   Start Trial   Start Trial   Start Trial
Pfizer Inc FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-004 Jan 30, 1998 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for FRAGMIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer Inc FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-001 Dec 22, 1994   Start Trial   Start Trial
Pfizer Inc FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-004 Jan 30, 1998   Start Trial   Start Trial
Pfizer Inc FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-003 Mar 18, 1996   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
AstraZeneca
Medtronic
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.